Yoshida K, Tachibana T
Department of Immunology, Tohoku University, Sendai, Japan.
Cancer Immunol Immunother. 1993 May;36(5):323-30. doi: 10.1007/BF01741171.
CD4+8- T lymphocytes with potent antitumor activity in vivo were obtained in peritoneal exudate cells by immunizing mice with irradiated MM48 tumor cells admixed with OK-432. These immune CD4+ T cells were used in adoptive immunotherapy for prevention of lymph node metastases after removal of the primary tumor. Complete cure of metastases was obtained by adoptive transfer of CD4+ T cells admixed with irradiated MM48 tumor cells, but not by CD4+ T cells alone. To analyze the curative effect of admixing tumor cells on the prevention of metastases, a model of 1-day tumor inoculated with macrophages was used. Administration of immune CD4+ T cells alone resulted in the regression of local tumor in more than half of the mice, although all of them eventually died of lymph node metastases. On the other hand, adoptive transfer of immune CD4+ T cells plus irradiated tumor cells resulted in the complete regression of local tumors in all the mice, which survived without any sign of metastasis. The curative effect of the immune CD4+ T cells obtained by admixing irradiated tumor cells was tumor-specific. Macrophages induced by OK-432 (tumoricidal), implanted together with tumor, assisted tumor regression more than did macrophages elicited by proteose peptone (non-tumoricidal) in the same adoptive transfer system. Administration of recombinant interleukin-2 instead of stimulant tumor cells did not enhance, but rather eliminated the constitutive antitumor activity of CD4+ T cells. On the other hand, exogenous recombinant interleukin-1 was more effective in the enhancement of antitumor activity of the CD4+ T cells as compared with stimulant tumor cell administration. In this case, the activating states of macrophages at the implanted tumor site had no influence on the therapeutic efficacy. A possible role of macrophages for induction of tumor-specific cytotoxic T cells that were mediated by tumor-specific CD4+ T cells is discussed.
通过用与OK-432混合的经辐照的MM48肿瘤细胞免疫小鼠,在腹膜渗出细胞中获得了在体内具有强大抗肿瘤活性的CD4+8-T淋巴细胞。这些免疫CD4+T细胞用于过继免疫疗法,以预防原发性肿瘤切除后的淋巴结转移。通过过继转移与经辐照的MM48肿瘤细胞混合的CD4+T细胞可实现转移灶的完全治愈,但单独使用CD4+T细胞则无法实现。为了分析混合肿瘤细胞对预防转移的治疗效果,使用了接种巨噬细胞的1日龄肿瘤模型。单独给予免疫CD4+T细胞导致超过一半的小鼠局部肿瘤消退,尽管它们最终都死于淋巴结转移。另一方面,过继转移免疫CD4+T细胞加经辐照的肿瘤细胞导致所有小鼠的局部肿瘤完全消退,这些小鼠存活且无任何转移迹象。通过混合经辐照的肿瘤细胞获得的免疫CD4+T细胞的治疗效果具有肿瘤特异性。在相同的过继转移系统中,与蛋白胨(非杀肿瘤性)诱导的巨噬细胞相比,OK-432(杀肿瘤性)诱导的巨噬细胞与肿瘤一起植入时对肿瘤消退的辅助作用更大。给予重组白细胞介素-2而非刺激性肿瘤细胞并未增强,反而消除了CD4+T细胞的固有抗肿瘤活性。另一方面,与给予刺激性肿瘤细胞相比,外源性重组白细胞介素-1在增强CD4+T细胞的抗肿瘤活性方面更有效。在这种情况下,植入肿瘤部位的巨噬细胞的激活状态对治疗效果没有影响。讨论了巨噬细胞在由肿瘤特异性CD4+T细胞介导的肿瘤特异性细胞毒性T细胞诱导中的可能作用。